Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674518 | 0.92 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL2516270 | 0.86 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL2516271 | 0.86 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL16884048 | 0.84 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL3905042 | 0.84 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL31489069 | 0.84 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL28046807 | 0.83 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL14168298 | 0.79 | ALDH1A1 (0.49) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL21070721 | 0.79 | ALDH1A1 (0.49) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL26091336 | 0.79 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847177-B1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | BOEHRINGER INGELHEIM INT (DE) | 2017-10-11 | — | — | EP | disclosed |
| EP-2847177-B1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | BOEHRINGER INGELHEIM INT (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9376409-B2 | Methods for making oxetan-3-ylmethanamines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-9376409-B2 | Methods for making oxetan-3-ylmethanamines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-9376409-B2 | Methods for making oxetan-3-ylmethanamines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150119589-A1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119589-A1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119589-A1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| EP-2847177-A1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | Boehringer Ingelheim International GmbH (DE) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169531-A1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119589-A1 | METHODS FOR MAKING OXETAN-3-YLMETHANAMINES | ODC1, PNMT, OXTR | L3MBTL1 2043/4885ALDH1A1 139/4885LMNA 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.